PL2020996T3 - Sposób i kompozycje do leczenia chorób nowotworowych układu krwiotwórczego - Google Patents

Sposób i kompozycje do leczenia chorób nowotworowych układu krwiotwórczego

Info

Publication number
PL2020996T3
PL2020996T3 PL07794933T PL07794933T PL2020996T3 PL 2020996 T3 PL2020996 T3 PL 2020996T3 PL 07794933 T PL07794933 T PL 07794933T PL 07794933 T PL07794933 T PL 07794933T PL 2020996 T3 PL2020996 T3 PL 2020996T3
Authority
PL
Poland
Prior art keywords
hematological malignancies
compositions
treating hematological
compound
salt
Prior art date
Application number
PL07794933T
Other languages
English (en)
Inventor
Lee S Chong
William A Lee
Adrian S Ray
Hans C Reiser
Daniel B Tumas
William J Watkins
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of PL2020996T3 publication Critical patent/PL2020996T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
PL07794933T 2006-05-16 2007-05-16 Sposób i kompozycje do leczenia chorób nowotworowych układu krwiotwórczego PL2020996T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US80098306P 2006-05-16 2006-05-16
US83180506P 2006-07-18 2006-07-18
EP07794933A EP2020996B1 (en) 2006-05-16 2007-05-16 Method and compositions for treating hematological malignancies
PCT/US2007/011726 WO2007136650A2 (en) 2006-05-16 2007-05-16 Method and compositions for treating hematological malignancies

Publications (1)

Publication Number Publication Date
PL2020996T3 true PL2020996T3 (pl) 2012-04-30

Family

ID=38578698

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07794933T PL2020996T3 (pl) 2006-05-16 2007-05-16 Sposób i kompozycje do leczenia chorób nowotworowych układu krwiotwórczego

Country Status (20)

Country Link
US (3) US20080039427A1 (pl)
EP (1) EP2020996B1 (pl)
JP (2) JP5544165B2 (pl)
KR (1) KR101424832B1 (pl)
CN (1) CN101442994B (pl)
AT (1) ATE534377T1 (pl)
AU (1) AU2007254309B2 (pl)
BR (1) BRPI0711646C1 (pl)
CA (1) CA2652048C (pl)
CY (1) CY1112377T1 (pl)
DK (1) DK2020996T3 (pl)
EA (1) EA016995B1 (pl)
ES (1) ES2377467T3 (pl)
HK (1) HK1127913A1 (pl)
MX (1) MX2008014665A (pl)
NZ (1) NZ572368A (pl)
PL (1) PL2020996T3 (pl)
PT (1) PT2020996E (pl)
SI (1) SI2020996T1 (pl)
WO (1) WO2007136650A2 (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
MX2008014024A (es) 2006-05-04 2008-11-14 Boehringer Ingelheim Int Formas poliformas.
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
AU2007254309B2 (en) * 2006-05-16 2012-05-03 Gilead Sciences, Inc. Method and compositions for treating hematological malignancies
TWI444384B (zh) 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
WO2010029089A2 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
WO2010072776A1 (en) 2008-12-23 2010-07-01 Boehringer Ingelheim International Gmbh Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
CN102753161A (zh) 2009-11-27 2012-10-24 贝林格尔.英格海姆国际有限公司 基因型糖尿病患者利用dpp-iv抑制剂例如利拉利汀的治疗
ES2935300T3 (es) 2010-05-05 2023-03-03 Boehringer Ingelheim Int Combiterapia
CN106975074A (zh) 2010-06-24 2017-07-25 勃林格殷格翰国际有限公司 糖尿病治疗
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
WO2013010964A1 (en) 2011-07-15 2013-01-24 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
BR112018072401A2 (pt) 2016-06-10 2019-02-19 Boehringer Ingelheim International Gmbh combinações de linagliptina e metformina
WO2019237957A1 (zh) * 2018-06-12 2019-12-19 四川科伦博泰生物医药股份有限公司 膦酰胺酯化合物及其盐和相关晶体形式、制备方法和用途
CN112168829B (zh) * 2020-09-24 2022-02-15 华南理工大学 抗病毒药物在制备治疗骨髓增生异常综合征药物中的应用及制得的骨髓增生异常综合征药物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
ES2536972T5 (es) 2000-07-21 2022-04-06 Gilead Sciences Inc Profármacos de análogos de nucleótidos de fosfonato y métodos para seleccionar y preparar los mismos
NZ539791A (en) * 2001-02-12 2006-11-30 Wyeth Corp Novel succinate salt of o-desmethyl-venlafaxine
RU2004116311A (ru) * 2001-11-29 2005-03-27 Пфайзер Продактс Инк. (Us) Сукцинатные соли 5,8,14-триазатетрацикло [10.3.1.02,11(04,9]гексадека- 2(11),3,5,7,9-пентаена и их фармацевтические композиции
JP4202926B2 (ja) * 2001-12-12 2008-12-24 ファイザー・プロダクツ・インク Ｅ−２−メトキシ−ｎ−（３−（４−（３−メチル−ピリジン−３−イロキシ）−フェニルアミノ）−キナゾリン−６−イル）−アリル）−アセトアミドの塩形態、その製造および癌に対するその使用
IL164809A0 (en) * 2002-05-13 2005-12-18 Metabasis Therapeutics Inc Novel phosphonic acid basdrugs of pmea and its analogues
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
NZ575575A (en) * 2003-08-18 2010-04-30 Lundbeck & Co As H Succinate and malonate salt of trans-4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament
PT2204374E (pt) * 2003-12-30 2012-09-17 Gilead Sciences Inc Fosfonatos nucleosídeos e seus análogos para o tratamento de infecções com hpv
DE602005017131D1 (de) 2004-01-21 2009-11-26 Gilead Sciences Inc Verwendung von adefovir oder tenofovir zur hemmung von mmtv-artigen viren im zusammenhang mit brustkrebs und primärer biliärer zirrhose
DE102005041860A1 (de) * 2005-09-02 2007-03-08 Schering Ag Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
TW200730530A (en) * 2005-12-16 2007-08-16 Wyeth Corp Lyophilized compositions of a triazolopyrimidine compound
AU2007254309B2 (en) * 2006-05-16 2012-05-03 Gilead Sciences, Inc. Method and compositions for treating hematological malignancies

Also Published As

Publication number Publication date
JP2013100324A (ja) 2013-05-23
ATE534377T1 (de) 2011-12-15
MX2008014665A (es) 2008-11-28
EP2020996B1 (en) 2011-11-23
SI2020996T1 (sl) 2012-03-30
US20090258840A1 (en) 2009-10-15
BRPI0711646B1 (pt) 2020-12-01
JP2009537539A (ja) 2009-10-29
HK1127913A1 (en) 2009-10-09
CA2652048C (en) 2012-12-11
KR101424832B1 (ko) 2014-08-06
AU2007254309A1 (en) 2007-11-29
CY1112377T1 (el) 2015-12-09
ES2377467T3 (es) 2012-03-27
DK2020996T3 (da) 2012-02-27
US8435969B2 (en) 2013-05-07
WO2007136650A2 (en) 2007-11-29
US20110172192A1 (en) 2011-07-14
NZ572368A (en) 2011-04-29
BRPI0711646B8 (pt) 2021-04-06
CA2652048A1 (en) 2007-11-29
CN101442994A (zh) 2009-05-27
KR20090015122A (ko) 2009-02-11
JP5544165B2 (ja) 2014-07-09
AU2007254309B2 (en) 2012-05-03
CN101442994B (zh) 2013-03-06
BRPI0711646C1 (pt) 2021-05-25
EA200802333A1 (ru) 2009-04-28
BRPI0711646A2 (pt) 2011-11-29
WO2007136650A3 (en) 2008-01-24
EA016995B1 (ru) 2012-09-28
EP2020996A2 (en) 2009-02-11
PT2020996E (pt) 2012-02-20
US20080039427A1 (en) 2008-02-14

Similar Documents

Publication Publication Date Title
HK1127913A1 (en) Method and compositions for treating hematological malignancies
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
MY150697A (en) Methods of treating cancer using pyridopyrimdinone inhibitors of p13k alpha
SG179418A1 (en) Inhibitors of the hedgehog pathway
HK1121440A1 (en) Biphenyl derivatives and their use in treating hepatitis c
TR201900306T4 (tr) Mek inhibitörlerini kullanma yöntemleri.
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
JO2848B1 (en) Organic compounds
EA200600689A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов raf киназы
MY150797A (en) Combination therapies comprising quinaxoline inhibitors of pi3k-alpha for use in the treatment of cancer
MX2009000657A (es) Composiciones y metodos para el tratamiento de mucositis.
HK1093159A1 (en) Monocyclic heterocycles as kinase inhibitors
MX2009005934A (es) Compuestos organicos.
UA85087C2 (en) Monocyclic heterocycles as kinase inhibitors
UA96969C2 (en) Acylaminopyrazoles as fgfr inhibitors
MX2011007165A (es) Derivados de piridazinona.
BRPI0821114A2 (pt) Composto, uso de um composto e método para tratar qualquer mamífero afetado por câncer
MX2011007232A (es) Derivados de benzotiazolona.
MX360417B (es) Fenilpropanoides digliceridos para el tratamiento del cancer.
NZ590076A (en) Treating plexiform neurofibroma and related tumors
TW200602023A (en) Monocyclic heterocycles as kinase inhibitors
TW200732314A (en) Substituted thiazoles and their use
MX2011007209A (es) Derivados de piridazinona.
UA97540C2 (ru) Замещенные хиноксалином пиперидиновые соединения и их применение
TH92470B (th) สารประกอบชนิดใหม่สำหรับการรักษาความผิดปกติทางประสาทวิทยา, จิตเวช หรืออาการปวด